ArticleMolecular and cellular biochemistry2014
Calreticulin is localized at mitochondria of rat cardiomyocytes and affected by furazolidone.
Article in Molecular and cellular biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Article
- Functional Analysis and Marker Development ofFrontiers in plant science · 2017Article
- Glycoprotein Quality Control and Endoplasmic Reticulum Stress.Molecules (Basel, Switzerland) · 2015Review
- Overexpression of a Triticum aestivum Calreticulin gene (TaCRT1) Improves Salinity Tolerance in Tobacco.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calreticulin (CRT) is a calcium-buffering protein which is predominantly located in endoplasmic reticulum. In the previous mitochondria proteome analysis, we accidentally found that CRT may be also localized at myocardial mitochondria and was upregulated in a rat model of furazolidone-induced dilated cardiomyopathy. To our knowledge, there has not yet been any report of its presence in mitochondria of any cell types. The present study aimed to determine whether CRT was located at the mitochondria of rat cardiomyocytes and whether the mitochondrial CRT was affected by furazolidone. Mitochondrial preparations were isolated from primary cultured neonatal rat cardiomyocytes and purified by differential centrifugation. The purity of mitochondria was assessed by the reduction or elimination of the immunoreactivities of markers for cytosol, nucleus, sarcolemma, and endoplasmic reticulum. Western blot analysis demonstrated the presence of CRT in purified mitochondria of rat cardiomyocytes. The distribution of CRT to mitochondria was further confirmed by immuno-electron microscopy, flow cytometry, and laser scanning confocal microscopy (double staining with MitoTracker Red and CRT-Alexa Fluor 488). Western blot analysis also demonstrated that the mitochondrial content of CRT was significantly enhanced by furazolidone treatment by 2.73 ± 0.13 fold (P < 0.05) in rat cardiomyocytes, which was verified by immuno-electron microscopy. In summary, the present results suggest that CRT is localized at mitochondria of rat cardiomyocytes and such localization is affected by furazolidone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.